PHD2/3-dependent hydroxylation tunes cardiac response to β-adrenergic stress via phospholamban

Journal of Clinical Investigation

Volumn 125, Issue 7, 2015, Pages 2759-2771

  Xie, Liang ^a   Pi, Xinchun ^a   Townley Tilson, W H Davin ^a   Li, Na ^a   Wehrens, Xander H T ^a   Entman, Mark L ^a   Taffet, George E ^a   Mishra, Ashutosh ^b   Peng, Junmin ^b   Schisler, Jonathan C ^c   Meissner, Gerhard ^c   Patterson, Cam ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CALMODULIN ACTIVATED KINASE II; ISOPRENALINE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PHOSPHOLAMBAN; PHOSPHOTRANSFERASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLINE; PROLYL HYDROXYLASE DOMAIN PROTEIN 2; PROLYL HYDROXYLASE DOMAIN PROTEIN 3; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; TAMOXIFEN; THYROID HORMONE RECEPTOR ALPHA; UNCLASSIFIED DRUG; BETA ADRENERGIC RECEPTOR; CALCIUM BINDING PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; EGLN1 PROTEIN, MOUSE; HIF1A PROTEIN, MOUSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; NCOR2 PROTEIN, MOUSE; PHD3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING AFFINITY; BLOOD PRESSURE; CONTROLLED STUDY; ENZYME ACTIVITY; HEART ARRHYTHMIA; HEART FUNCTION; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE INJURY; HEART RATE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEK293 CELL LINE; HYDROXYLATION; HYPOXIA; IMMUNOBLOTTING; MALE; MASS SPECTROMETRY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; TUNEL ASSAY; WESTERN BLOTTING; ANIMAL; CALCIUM SIGNALING; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CELL CULTURE; DEFICIENCY; FEMALE; GENETICS; HEART CONTRACTION; HEART MUSCLE ISCHEMIA; HUMAN; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGICAL STRESS; PHYSIOLOGY; RAT; TRANSGENIC MOUSE;

ANIMALS; CALCIUM SIGNALING; CALCIUM-BINDING PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CELLS, CULTURED; FEMALE; HUMANS; HYDROXYLATION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; MYOCYTES, CARDIAC; NUCLEAR RECEPTOR CO-REPRESSOR 2; PROCOLLAGEN-PROLINE DIOXYGENASE; RATS; RECEPTORS, ADRENERGIC, BETA; STRESS, PHYSIOLOGICAL; THYROID HORMONE RECEPTORS ALPHA;

EID: 84936745408     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI80369     Document Type: Article

References (57)

1. Roger VL, et al. Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation. 2012;125(1):e2-e220.
2. Schomig A. Adrenergic mechanisms in myocardial infarction: cardiac and systemic catecholamine release. J Cardiovasc Pharmacol. 1988;12(suppl 1):S1-S7.
3. Desantiago J, et al. Arrhythmogenic effects of β2-adrenergic stimulation in the failing heart are attributable to enhanced sarcoplasmic reticulum Ca load. Circ Res. 2008;102(11):1389-1397.
4. Bristow MR. β-Adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101(5):558-569.
5. Kushner FG, et al. 2009 Focused Updates: ACC/ AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120(22):2271-2306.
6. Van de Werf F, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29(23):2909-2945.
7. Grimm M, Brown JH. β-Adrenergic receptor signaling in the heart: role of CaMKII. J Mol Cell Cardiol. 2010;48(2):322-330.
8. Swaminathan PD, Purohit A, Hund TJ, Anderson ME. Calmodulin-dependent protein kinase II: linking heart failure and arrhythmias. Circ Res. 2012;110(12):1661-1677.
9. Rokita AG, Anderson ME. New therapeutic targets in cardiology: arrhythmias and Ca2+/calmodulin-dependent kinase II (CaMKII). Circulation. 2012;126(17):2125-2139.
10. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. Mol Cell. 2008;30(4):393-402.
11. Aravind L, Koonin EV. The DNA-repair protein AlkB, EGL-9, and leprecan define new families of 2-oxoglutarate-and iron-dependent dioxygenases. Genome Biol. 2001;2(3):RESEARCH0007.
12. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001;294(5545):1337-1340.
13. Jaakkola P, et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516):468-472.
14. Ivan M, et al. HIFalpha targeted for VHLmediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464-468.
15. Freeman RS, Hasbani DM, Lipscomb EA, Straub JA, Xie L. SM-20, EGL-9, and the EGLN family of hypoxia-inducible factor prolyl hydroxylases. Mol Cells. 2003;16(1):1-12.
16. Willam C, et al. HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation. J Mol Cell Cardiol. 2006;41(1):68-77.
17. Nwogu JI, Geenen D, Bean M, Brenner MC, Huang X, Buttrick PM. Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation. 2001;104(18):2216-2221.
18. Holscher M, et al. Cardiomyocyte-specific prolyl-4-hydroxylase domain 2 knock out protects from acute myocardial ischemic injury. J Biol Chem. 2011;286(13):11185-11194.
19. Eckle T, Kohler D, Lehmann R, El Kasmi K, Eltzschig HK. Hypoxia-inducible factor-1 is central to cardioprotection: A new paradigm for ischemic preconditioning. Circulation. 2008;118(2):166-175.
20. Xie L, Pi X, Wang Z, He J, Willis MS, Patterson C. Depletion of PHD3 protects heart from ischemia/ reperfusion injury by inhibiting cardiomyocyte apoptosis. J Mol Cell Cardiol. 2015;80:156-165.
21. Kido M, et al. Hypoxia-inducible factor 1-α reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol. 2005;46(11):2116-2124.
22. Minamishima YA, et al. A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo. Mol Cell Biol. 2009;29(21):5729-5741.
23. Moslehi J, et al. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation. 2010;122(10):1004-1016.
24. Xie L, et al. Oxygen-regulated beta(2)-adrenergic receptor hydroxylation by EGLN3 and ubiquitylation by pVHL. Sci Signal. 2009;2(78):ra33.
25. Xie L, Pi X, Mishra A, Fong G, Peng J, Patterson C. PHD3-dependent hydroxylation of HCLK2 promotes the DNA damage response. J Clin Invest. 2012;122(8):2827-2836.
26. Luo W, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell. 2011;145(5):732-744.
27. Marks AR. Calcium cycling proteins and heart failure: mechanisms and therapeutics. J Clin Invest. 2013;123(1):46-52.
28. Yano M, Ikeda Y, Matsuzaki M. Altered intracellular Ca2+ handling in heart failure. J Clin Invest. 2005;115(3):556-564.
29. Belakavadi M, Saunders J, Weisleder N, Raghava PS, Fondell JD. Repression of cardiac phospholamban gene expression is mediated by thyroid hormone receptor-{alpha}1 and involves targeted covalent histone modifications. Endocrinology. 2010;151(6):2946-2956.
30. Takeda K, et al. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood. 2008;111(6):3229-3235.
31. Yang Y, et al. Calmodulin kinase II inhibition protects against myocardial cell apoptosis in vivo. Am J Physiol Heart Circ Physiol. 2006;291(6):H3065-H3075.
32. Wu Y, et al. Suppression of dynamic Ca(2+) transient responses to pacing in ventricular myocytes from mice with genetic calmodulin kinase II inhibition. J Mol Cell Cardiol. 2006;40(2):213-223.
33. Wehrens XH, Lehnart SE, Reiken SR, Marks AR. Ca2+/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res. 2004;94(6):e61-70.
34. Maier LS, Bers DM. Role of Ca2+/calmodulin-dependent protein kinase (CaMK) in excitation-contraction coupling in the heart. Cardiovasc Res. 2007;73(4):631-640.
35. Cross HR, Kranias EG, Murphy E, Steenbergen C. Ablation of PLB exacerbates ischemic injury to a lesser extent in female than male mice: protective role of NO. Am J Physiol Heart Circ Physiol. 2003;284(2):H683-H690.
36. Epstein AC, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107(1):43-54.
37. Deribe YL, Pawson T, Dikic I. Post-translational modifications in signal integration. Nat Struct Mol Biol. 2010;17(6):666-672.
38. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature. 1995;377(6548):454-457.
39. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: A manifestation of coronary artery disease. Circulation. 1998;97(3):282-289.
40. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005; 111(25):3481-3488.
41. Spencer FA, Meyer TE, Gore JM, Goldberg RJ. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure: The National Registry of Myocardial Infarction. Circulation. 2002;105(22):2605-2610.
42. May D, et al. Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation. Proc Natl Acad Sci U S A. 2008;105(1):282-287.
43. Semenza GL. Hypoxia-inducible factor 1 and cardiovascular disease. Annu Rev Physiol. 2014;76:39-56.
44. Bosch-Marce M, et al. Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. Circ Res. 2007;101(12):1310-1318.
45. Sano M, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature. 2007;446(7134):444-448.
46. Bekeredjian R, et al. Conditional HIF-1α expression produces a reversible cardiomyopathy. PLoS One. 2010;5(7):e11693.
47. Bers DM. Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol. 2008;70:23-49.
48. Frank K, Kranias EG. Phospholamban and cardiac contractility. Ann Med. 2000;32(8):572-578.
49. Luo W, et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ Res. 1994;75(3):401-409.
50. Minamisawa S, et al. Kranias EG, et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell. 1999;99(3):313-322.
51. Sato Y, et al. Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation. J Biol Chem. 2001;276(12):9392-9399.
52. Haghighi K, et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest. 2003;111(6):869-876.
53. Moresi V, et al. Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases. Cell. 2010;143(1):35-45.
54. Claycomb WC, et al. HL-1 cells: A cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A. 1998;95(6):2979-2984.
55. Yamaguchi N, Takahashi N, Xu L, Smithies O, Meissner G. Early cardiac hypertrophy in mice with impaired calmodulin regulation of cardiac muscle Ca release channel. J Clin Invest. 2007;117(5):1344-1353.
56. Xu P, Duong DM, Peng J. Systematical optimization of reverse-phase chromatography for shotgun proteomics. J Proteome Res. 2009;8(8):3944-3950.
57. Ma B, et al. PEAKS: powerful software for peptide de novo sequencing by tandem mass spectrometry. Rapid Commun Mass Spectrom. 2003;17(20):2337-2342.